Treatments
TL;DR: 73 FDA-approved drugs have labels that mention lung cancer in their indications. Grouped below by mechanism of action. This list gives you the vocabulary — your oncologist chooses a regimen based on your specific subtype, stage, biomarkers, and prior therapies.
Source: OpenFDA drug label API · last checked
Cost transparency
Drugs below have published Medicare Part B or Part D spending figures — what the federal government actually paid per beneficiary in 2023.
Immunotherapy (PD-1 inhibitor)
Immunotherapy (PD-1 inhibitor)
Immunotherapy (CTLA-4 inhibitor)
Immunotherapy (PD-L1 inhibitor)
Antibody-drug conjugate (HER2)
Targeted antibody (VEGF)
Bone-targeted (RANKL inhibitor)
Targeted oral (EGFR inhibitor)
Figures are average Medicare spending per beneficiary. Out-of-pocket varies by insurance and manufacturer assistance. See all drug costs →
Drugs that activate or modify the immune system to attack cancer cells. Checkpoint inhibitors (targeting PD-1, PD-L1, CTLA-4) are the most common.
Programmed Death Receptor-1 Blocking Antibody [EPC] · Programmed Death Receptor-1-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage…
Programmed Death Receptor-1 Blocking Antibody [EPC] · Endoglycosidase [EPC]
From the FDA label: 1 INDICATIONS AND USAGE TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment fol…
From the FDA label: 1 INDICATIONS AND USAGE LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or l…
Programmed Death Ligand-1 Blocker [EPC] · Programmed Death Ligand-1 Antagonists [MoA]
From the FDA label: 1 INDICATIONS AND USAGE IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant…
CTLA-4-directed Blocking Antibody [EPC] · CTLA-4-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single…
Programmed Death Receptor-1 Blocking Antibody [EPC] · Programmed Death Receptor-1-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agen…
Programmed Death Receptor-1 Blocking Antibody [EPC] · Endoglycosidase [EPC]
From the FDA label: 1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients…
Programmed Death Receptor-1 Blocking Antibody [EPC] · Programmed Death Receptor-1-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric…
Endoglycosidase [EPC] · Programmed Death Receptor-1 Blocking Antibody [EPC]
From the FDA label: 1 INDICATIONS AND USAGE KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with un…
CTLA-4-directed Blocking Antibody [EPC] · CTLA-4-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: • in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). (…
Monoclonal antibodies and antibody-drug conjugates (ADCs) that bind specific proteins on cancer cells.
Vascular Endothelial Growth Factor Inhibitor [EPC] · Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatm…
Vascular Endothelial Growth Factor Inhibitor [EPC] · Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE VEGZELMA is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treat…
Vascular Endothelial Growth Factor Inhibitor [EPC] · Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatmen…
Vascular Endothelial Growth Factor Inhibitor [EPC] · Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE ZIRABEV is a vascular endothelial growth factor inhibitor indicated for the treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line trea…
From the FDA label: 1 INDICATIONS AND USAGE Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatm…
Vascular Endothelial Growth Factor Inhibitor [EPC] · Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Jobevne is a vascular endothelial growth factor inhibitor indicated for the treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first-or second-line treat…
From the FDA label: 1 INDICATIONS AND USAGE DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-smal…
From the FDA label: 1 INDICATIONS AND USAGE ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated: HER2-Positive Metastatic Breast Cancer in combination with pertuzumab as first-line treatment of adult patients with unresectable o…
From the FDA label: 1 INDICATIONS AND USAGE EMRELIS is indicated for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3…
From the FDA label: 1 INDICATIONS AND USAGE BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fu…
Small-molecule drugs taken by mouth that block specific molecular pathways driving cancer growth (kinases, PARP, CDK4/6, etc.).
Kinase Inhibitor [EPC] · Protein Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as d…
From the FDA label: 1 INDICATIONS AND USAGE ALECENSA is a kinase inhibitor indicated for: adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node posi…
From the FDA label: 1 INDICATIONS AND USAGE MEKTOVI is a kinase inhibitor indicated: • in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved t…
Kinase Inhibitor [EPC] · Tyrosine Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administratio…
From the FDA label: 1 INDICATIONS AND USAGE TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as dete…
Kinase Inhibitor [EPC] · Tyrosine Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE ZYKADIA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test [see Dosage…
Kinase Inhibitor [EPC] · Cytochrome P450 3A Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FD…
From the FDA label: 1 INDICATIONS AND USAGE TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR i…
From the FDA label: 1 INDICATIONS AND USAGE VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations
From the FDA label: 1 INDICATIONS AND USAGE BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-…
From the FDA label: 1 INDICATIONS AND USAGE ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)as detected by an FDA-approved test [see Dosag…
From the FDA label: 1 INDICATIONS AND USAGE ROZLYTREK is a kinase inhibitor indicated for the treatment of: Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1.1 ) Adult and pediatric patien…
From the FDA label: 1 INDICATIONS AND USAGE Erlotinib tablets are a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon…
From the FDA label: 1 INDICATIONS AND USAGE Erlotinib tablet is a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 2…
Topoisomerase Inhibitor [EPC] · Topoisomerase Inhibitors [MoA]
From the FDA label: INDICATIONS AND USAGE Etoposide Injection is indicated in the management of the following neoplasms: Refractory Testicular Tumors Etoposide Injection in combination therapy with other approved chemotherapeutic agents in patients with refrac…
Kinase Inhibitor [EPC] · Protein Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858…
Kinase Inhibitor [EPC] · Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGF…
Kinase Inhibitor [EPC] · Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. LORBRENA
Alkylating Drug [EPC] · Alkylating Activity [MoA]
From the FDA label: 1 INDICATIONS AND USAGE ZEPZELCA is an alkylating drug indicated: • in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose d…
Kinase Inhibitor [EPC] · Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE TAGRISSO is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 delet…
Kinase Inhibitor [EPC] · Rearranged during Transfection (RET) Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC). (…
Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] · VEGFR2 Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or ga…
Kinase Inhibitor [EPC] · Proto-Oncogene Tyrosine-Protein Kinase ROS1 Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE AUGTYRO is a kinase inhibitor indicated for the treatment of • adult patients with locally advanced or metastatic ROS1- positive non-small cell lung cancer (NSCLC). ( 1.1 ) • adult and pediatric patients 12 years of
Kinase Inhibitor [EPC] · Rearranged during Transfection (RET) Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detect…
From the FDA label: 1 INDICATIONS AND USAGE HYRNUO is indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2 ) tyrosine kinase domain (TKD) activating mut…
From the FDA label: 1 INDICATIONS AND USAGE IBTROZI ® (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) [see Dosage and Administration ( 2.1 )] . IBTROZI is a
From the FDA label: 1 INDICATIONS AND USAGE TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. TEPMETKO is a kinase inhi…
From the FDA label: 1 INDICATIONS AND USAGE MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FD…
From the FDA label: 1 INDICATIONS AND USAGE COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensiv…
Kinase Inhibitor [EPC] · HER2/Neu/cerbB2 Antagonists [MoA]
From the FDA label: 1 INDICATIONS AND USAGE HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, a…
Cytotoxic drugs that kill rapidly dividing cells. Includes platinums, taxanes, antimetabolites, alkylators, topoisomerase inhibitors, and anthracyclines.
From the FDA label: 1 INDICATIONS AND USAGE Docetaxel injection is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant
Microtubule Inhibitor [EPC]
From the FDA label: 1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant…
From the FDA label: 1 INDICATIONS AND USAGE ETOPOPHOS is a topoisomerase inhibitor indicated for the treatment of patients with: Refractory testicular tumors, in combination with other chemotherapeutic drugs. ( 1 ) Small cell lung cancer, in combination with c…
From the FDA label: 1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-base…
From the FDA label: 1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-ba…
Folate Analog Metabolic Inhibitor [EPC] · Folic Acid Metabolism Inhibitors [MoA]
From the FDA label: INDICATIONS AND USAGE Neoplastic Diseases Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis
From the FDA label: INDICATIONS AND USAGE: Neoplastic Diseases Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in mainten…
Microtubule Inhibitor [EPC]
From the FDA label: INDICATIONS AND USAGE Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin. Paclitaxel…
Microtubule Inhibitor [EPC]
From the FDA label: 1 INDICATIONS AND USAGE Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastat…
Microtubule Inhibitor [EPC]
From the FDA label: 1 INDICATIONS AND USAGE Paclitaxel is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Pr…
From the FDA label: 1 INDICATIONS AND USAGE Topotecan Injection is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. Topotecan…
From the FDA label: 1 INDICATIONS AND USAGE Topotecan Hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a si…
From the FDA label: 1 INDICATIONS AND USAGE Vinorelbine Injection is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent for the treatment of pat…
Drugs whose pharmacologic class was not automatically classified into the groups above. Check the FDA label for mechanism details.
From the FDA label: 1 INDICATIONS AND USAGE KRAZATI is an inhibitor of the RAS GTPase family indicated for: Non-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC…
Endoglycosidase [EPC] · Glycoside Hydrolases [CS]
From the FDA label: 1 INDICATIONS AND USAGE RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-l…
From the FDA label: 1 INDICATIONS AND USAGE RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-smal…
Epidermal Growth Factor Receptor Antagonist [EPC] · HER1 Antagonists [MoA]
From the FDA label: 1 INDICATIONS AND USAGE PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.
From the FDA label: 1 INDICATIONS AND USAGE PEMFEXY™ is a folate analog metabolic inhibitor indicated for: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or AL…
Folate Analog Metabolic Inhibitor [EPC] · Folic Acid Metabolism Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Pemetrexed for Injection is a folate analog metabolic inhibitor indicated: in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a sin…
From the FDA label: 1. INDICATIONS AND USAGE PEMRYDI RTU ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung can…
From the FDA label: 1 INDICATIONS AND USAGE PHOTOFRIN is a photoactivated radical generator indicated for: Esophageal Cancer ( 1.1 ) Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal canc…
From the FDA label: 1 INDICATIONS AND USAGE LUMAKRAS is an inhibitor of the RAS GTPase family indicated for: KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G1…
From the FDA label: 1 INDICATIONS AND USAGE IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA is a bispecific delta-like
Disease foundations below have active funds covering lung cancer medications. Manufacturer patient-assistance programs are listed on each drug's cost page.
copay, premium, and deductible assistance for insured patients; fund availability varies by disease
https://www.healthwellfoundation.org/disease-funds/Funds open and close based on availability; check disease-funds page for current status
copay assistance for 20+ cancer types via disease-specific funds
https://www.panfoundation.org/find-disease-fund/Merging with Patient Advocate Foundation; unified 'TotalAssist' program launches 2026-07-01
direct copay / coinsurance assistance via disease-specific funds
https://copays.org/Merging with PAN Foundation; launching 'TotalAssist' 2026-07-01
copay assistance for chemotherapy and targeted treatment medications
https://www.cancercare.org/copayfoundationlimited financial assistance for transportation, home care, child care, and treatment-related costs
https://www.cancercare.org/financialTrials test new therapies before they are FDA-approved. Often a way to access tomorrow's drugs today.
Back to Lung Cancer hub →Stats, second opinions, NCI cancer centers, oncologists.
Understand biomarkers →Most targeted therapies require biomarker testing. Here's what you need to know.
Read your pathology report →Which drugs apply to you depends on what's in your pathology.